{{위키데이터 속성 추적}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461093150
| drug_name = 
| INN = 
| type = <!-- empty -->
| image = eltrombopag.svg
| width = 270
| alt = 
| caption = 

<!-- Clinical data -->
| pronounce = 
| tradename = 프로막타, 레볼레이드, 알바이즈(Alvaiz)
| Drugs.com = {{drugs.com|monograph|eltrombopag}}
| MedlinePlus = a609011
| licence_EU = yes
| INN_EMA = eltrombopag olamine
| DailyMedID = Eltrombopag_olamine
| licence_US = Eltrombopag
| pregnancy_AU = B3
| pregnancy_AU_comment =<ref name="Revolade TGA label" />
| pregnancy_category =
| dependency_liability =
| routes_of_administration = [[경구 투여]]
| class = 
| ATC_prefix = B02
| ATC_suffix = BX05
| ATC_supplemental = 

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment =<ref name="Revolade TGA label">{{웹 인용| title=Revolade Product Information | website=[[Therapeutic Goods Administration]] (TGA) | url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-01377-3 | access-date=23 May 2021 | archive-date=23 May 2021 | archive-url=https://web.archive.org/web/20210523204750/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-01377-3 | url-status=live }}</ref>
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = POM
| legal_UK_comment =<ref>{{웹 인용| title=Revolade 25 mg film-coated tablets - Summary of Product Characteristics (SmPC) | website=(emc) | date=17 August 2020 | url=https://www.medicines.org.uk/emc/product/7819/smpc | access-date=22 May 2021 | archive-date=23 May 2021 | archive-url=https://web.archive.org/web/20210523051334/https://www.medicines.org.uk/emc/product/7819/smpc | url-status=live }}</ref>
| legal_US = Rx-only
| legal_US_comment =<ref name="Promacta FDA label">{{웹 인용| title=Promacta- eltrombopag olamine tablet, film coated Promacta- eltrombopag olamine powder, for suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2 | access-date=22 May 2021 | archive-date=23 May 2021 | archive-url=https://web.archive.org/web/20210523051335/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2 | url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref name="Revolade EPAR">{{웹 인용| title=Revolade EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/revolade | access-date=22 May 2021 | archive-date=23 May 2021 | archive-url=https://web.archive.org/web/20210523051333/https://www.ema.europa.eu/en/medicines/human/EPAR/revolade | url-status=live }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment = 
| legal_status = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability = ~52%<ref name="Promacta FDA label" />
| protein_bound = >99%
| metabolism = 대부분 [[간]]에서 대사 ([[CYP1A2]], [[CYP2C8]])
| metabolites = 
| onset = 
| elimination_half-life = 21~35시간
| duration_of_action = 
| excretion = 대변 (59%), 소변 (31%)

<!-- Identifiers -->
| index2_label = as olamine
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 496775-61-2
| CAS_number2 = 496775-62-3
| CAS_supplemental = 
| PubChem = 9846180
| PubChem2 = 135449331
| IUPHAR_ligand = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06210
| DrugBank2 = DBSALT000063
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21106301
| ChemSpiderID2 = 28475107
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S56D65XJ9G
| UNII2 = 4U07F515LG
| KEGG_Ref = 
| KEGG = D03978
| ChEBI_Ref = 
| ChEBI = 85010
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 461101
| ChEMBL2 = 3989691
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = SB-497115-GR

<!-- Chemical and physical data -->
| IUPAC_name = 3'-{(2''Z'')-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4''H''-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid
| C=25 | H=22 | N=4 | O=4
| SMILES = CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22-
| StdInChI_comment = 
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XDXWLKQMMKQXPV-QYQHSDTDSA-N
| density = 
| density_notes = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| sol_units = 
| specific_rotation = 
}}

'''엘트롬보팍'''(Eltrombopag)은 [[혈소판]] 수가 떨어지는 [[혈소판감소증]], 그리고 중증 [[재생불량성 빈혈]] 치료에 사용되는 약물로, '''프로막타'''(Promacta) 등의 상품명으로 판매되는 중이다.<ref name="Promacta FDA label" /><ref name="Revolade EPAR" /> 대한민국을 포함한 미국 이외 국가에서는 '''레볼레이드'''(Revolade)라는 상품명으로 [[노바티스]]가 시판 중이다.<ref name=":0">{{보도자료 인용|date=5 March 2019|title=Ligand Sells Promacta Assets and Royalty for $827 Million|url=https://www.businesswire.com/news/home/20190305005956/en/Ligand-Sells-Promacta-Assets-and-Royalty-for-827-Million|access-date=17 June 2021|publisher=Ligand Pharmaceuticals|via=Business Wire|archive-date=24 June 2021|archive-url=https://web.archive.org/web/20210624200825/https://www.businesswire.com/news/home/20190305005956/en/Ligand-Sells-Promacta-Assets-and-Royalty-for-827-Million|url-status=live}}</ref> [[트롬보포이에틴 수용체]] 작용제에 속한다.<ref name="Promacta FDA label" /> [[경구 투여]] 약제이다.<ref name="Promacta FDA label" /><ref name="Revolade EPAR" />

[[글락소스미스클라인]]과 [[리간드 파마슈티컬스]]의 공동 연구를 통해 발견되었으며, 이후 노바티스로 권리가 넘어갔다.<ref name=":0" /><ref>{{웹 인용|title=Revolade |url=http://ca.gsk.com/en-ca/products/revolade/ |access-date=17 June 2021 |website=GSK Canada |archive-date=28 June 2021 |archive-url=https://web.archive.org/web/20210628033247/https://ca.gsk.com/en-ca/products/revolade/ |url-status=dead }}</ref><ref>{{보도자료 인용|title=Novartis announces completion of transactions with GSK|url=https://www.sandoz.com/news/media-releases/novartis-announces-completion-transactions-gsk|access-date=17 June 2021|website=Sandoz|archive-date=24 June 2021|archive-url=https://web.archive.org/web/20210624201927/https://www.sandoz.com/news/media-releases/novartis-announces-completion-transactions-gsk|url-status=live}}</ref>

== 의학적 사용 ==
2008년 11월 20일, [[미국 식품의약국]](FDA)은 [[코르티코스테로이드]], [[면역글로불린 치료]], [[비장절제술]]을 받고도 치료 반응이 충분하지 않은 만성 [[특발성 혈소판 감소성 자반증]](ITP) 환자에 대해 엘트롬보팍 사용을 승인했다.<ref>{{웹 인용|title=Approval Letter|url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022291s000ltr.pdf|publisher=U.S. [[Food and Drug Administration]] (FDA)|access-date=18 March 2016|archive-date=28 February 2017|archive-url=https://web.archive.org/web/20170228134225/http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022291s000ltr.pdf|url-status=live}}</ref><ref>{{웹 인용| title=Drug Approval Package: Promacta (Eltrombopag) NDA #022291 | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=14 January 2009 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_TOC.cfm | access-date=22 May 2021 | archive-date=3 April 2021 | archive-url=https://web.archive.org/web/20210403054745/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_TOC.cfm | url-status=live }}</ref><ref>{{웹 인용| title=Summary Review | publisher=U.S. [[Food and Drug Administration]] (FDA) | date=19 January 2008 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_SumR.pdf | access-date=22 May 2021 | archive-date=23 May 2021 | archive-url=https://web.archive.org/web/20210523051334/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022291s000_SumR.pdf | url-status=live }}</ref>

2015년 8월 24일, FDA는 코르티코스테로이드, 면역글로불린, 비장절제술에 대한 반응이 충분치 않았던 1살 이상 소아의 특발성 혈소판감소증의 치료에 대해 사용을 승인했다.<ref>{{보도자료 인용|title=FDA extends use of Promacta in young children with rare blood disorder|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm459430.htm|publisher=U.S. [[Food and Drug Administration]] (FDA)|access-date=18 March 2016|archive-date=26 January 2018|archive-url=https://web.archive.org/web/20180126103132/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm459430.htm|url-status=dead}}</ref>

2014년 2월, FDA는 엘트롬보팍을 [[면역억제]] 치료가 성공하지 못한 [[재생불량성 빈혈]] 환자에 대한 [[획기적 치료]]로 지정했다.<ref>{{웹 인용|title=Eltrombopag / Promacta|url=https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm|publisher=U.S. [[Food and Drug Administration]] (FDA)|access-date=18 March 2016|archive-date=6 December 2016|archive-url=https://web.archive.org/web/20161206124948/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm|url-status=live}}</ref> 2017년, NIH는 엘트롬보팍을 재생불량성 빈혈의 표준 치료제로 추가했다.<ref>{{저널 인용| vauthors = Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O, Weinstein B, Valdez J, Lotter J, Feng X, Desierto M, Leuva H, Bevans M, Wu C, Larochelle A, Calvo KR, Dunbar CE, Young NS | display-authors = 6 | title = Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia | journal = The New England Journal of Medicine | volume = 376 | issue = 16 | pages = 1540–1550 | date = April 2017 | pmid = 28423296 | pmc = 5548296 | doi = 10.1056/NEJMoa1613878 | doi-access = free }}</ref> 엘트롬보팍을 재생불량성 빈혈의 면역억제 치료에 이용할 시 [[항흉선세포글로불린]](ATG), [[사이클로스포린]]과 병용한다.<ref>{{웹 인용|url=https://www.niddk.nih.gov/health-information/blood-diseases/aplastic-anemia-myelodysplastic-syndromes/treatment|제목=Treatment of Aplastic Anemia & Myelodysplastic Syndromes - NIDDK|언어=en-US|확인날짜=2024-05-02}}</ref>

== 각주 ==
{{각주}}

== 외부 링크 ==
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/eltrombopag | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Eltrombopag }}
* {{웹 인용| url = https://druginfo.nlm.nih.gov/drugportal/name/eltrombopag%20olamine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Eltrombopag olamine}}
* {{ClinicalTrialsGov|NCT00102739|SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)}}
* {{ClinicalTrialsGov|NCT00370331|RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)}}
* {{ClinicalTrialsGov|NCT00351468|EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)}}
* {{ClinicalTrialsGov|NCT01520909|Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)}}
* {{ClinicalTrialsGov|NCT00908037|Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (PETIT)}}
* {{ClinicalTrialsGov|NCT00516321|Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease}}
* {{ClinicalTrialsGov|NCT00529568|Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease}}
* {{ClinicalTrialsGov|NCT01623167|Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia}}
* {{ClinicalTrialsGov|NCT00922883|A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients}}

[[분류:바이페닐]]
[[분류:카복실산]]
[[분류:혈액 및 조혈기관에 작용하는 약]]
[[분류:하이드라진]]
[[분류:희귀약]]
[[분류:트롬보포이에틴 수용체 작용제]]
[[분류:글락소스미스클라인의 제품]]
[[분류:노바티스의 제품]]